BioNTech ups its production capacity to support cell therapy clinical trials by acquiring Kite’s R&D platform and gaining a facility in Gaithersburg, Maryland. The deal, of which financial details have not been disclosed, sees BioNTech acquire Gilead Sciences’ Kite Pharma’s solid tumor neoantigen T cell receptor (TCR) R&D technology. The deal will also see BioNTech take over the lease at the Gaithersburg manufacturing facility. BioNTech became a household name after BNT162b2 became the first messenger RNA (mRNA) COVID-19 vaccine to…